Clinical Trials Logo

Clinical Trial Summary

Background: - Plexiform neurofibromas are tumors that grow in and around nerves. The only way to treat them is with surgery. Some of these tumors cannot be completely removed. The tumors may be too large, too numerous, or in a bad location for surgery. An experimental drug called AZD6244 hydrogen sulfate may be able to prevent the tumors from growing, slow down their growth, or shrink them. This drug has been tested in adults with cancer and in children with some types of brain cancer. This study will test how well this drug works with these types of tumors. Objectives: - To study the safety and effectiveness of AZD6244 hydrogen sulfate in children and young adults with plexiform neurofibromas that cannot be completely removed by surgery. Eligibility: - Children and young adults between 12 and 18 years of age who have plexiform neurofibromas that cannot be completely removed by surgery. Design: - Patients will be screened with a physical exam, medical history, blood tests, and imaging studies. - They will take the study drug twice a day with 8 ounces of water, every day for 28-day cycles of treatment. During study visits, participants will have blood and urine tests and physical exams. They will also have imaging studies to examine the tumor sizes and locations. They will answer questions about their health. They may have other tests as needed. - Participants will continue to receive the study drug as long as they have no severe side effects and the disease is not getting worse.


Clinical Trial Description

Background - Patients with Neurofibromatosis 1 (NF1) have an increased risk of developing tumors of the central and peripheral nervous system, including plexiform neurofibromas (PN), which are benign nerve sheath tumors that are among the most debilitating complications of NF1. PN may be congenital and appear to have the fastest growth rate in young children. Surgery is the only standard treatment option available for PN. However, this is often difficult due to the encasement of vital structures, and extensive and invasive PN growth. - PN are composed of neoplastic Schwann cells that lack NF1 gene expression. This results in upregulation of Ras, which initiates several signaling cascades regulating cell proliferation. - Selumetinib (AZD6244 hyd sulfate), a novel orally bioavailable mitogen activated protein kinase inhibitor, is a specific inhibitor of MEK 1, which may mediate anti-tumor effects in PN by inhibition of downstream signaling of Ras. Selumetinib is currently undergoing evaluation in adult cancers and children with brain tumors. - In this phase I study of selumetinib directed at NF1 PN, we have observed a degree of activity which has not been observed previously; therefore a phase II evaluation will be conducted Objectives Phase I: - To determine the maximum tolerated dose (MTD) of oral selumetinib administered daily to pediatric patients with NF1 and inoperable PN. Based on the results of the dose escalation in this study, the current MTD has been determined as 20 mg/m2/dose. To be consistent in pediatric dosing, an additional dose level of 25 mg/m2/dose was added, which is the MTD recently determined in a study conducted by the Pediatric Brain Tumor Consortium (PBTC). Amendment H (November 2014): The MTD has been determined to be 25 mg/m(2)/dose. - To define the acute and chronic toxicities and pharmacokinetics (PK) of selumetinib. Completed with amendment H. Phase II: -Primary objectives: To evaluate the confirmed partial and complete response rate of selumetinib using volumetric MRI analysis in children and young adults with NF1 and inoperable PN with PN related morbidity at the time of enrollment. Eligibility Pediatric Patients (greater than or equal to 2 and less than or equal to 18 years) who are able to swallow intact capsules, with NF1 and inoperable measurable PN that have the potential to cause significant morbidity. Design - Selumetinib will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment cycle). In the phase I portion, limited dose escalations will be performed to define the MTD based on tolerability of selumetinib during the first three treatment cycles. In the phase II portion, the recommended phase II dose level (RP2D) will be administered. - Phase II: Patients will be enrolled on one of two strata: - Stratum 1: PN related morbidity present at enrollment ---PN related pain, disfigurement, or difficulty in physical functioning - Stratum 2: No significant PN related morbidity present at enrollment, but potential for development of PN morbidity - Patient reported and functional outcomes will be evaluated at regular intervals. - Disease status will be evaluated using volumetric MRI analysis at regular intervals. - The day 1 and steady state plasma PK and PD of selumetinib will be evaluated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01362803
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date September 21, 2011
Completion date January 1, 2030

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Recruiting NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting NCT01218139 - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients N/A
Recruiting NCT05149469 - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting NCT02505412 - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients N/A
Terminated NCT02256124 - Effect of Lamotrigine on Cognition in NF1 Phase 2/Phase 3
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Active, not recruiting NCT01218152 - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs N/A
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05186870 - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Withdrawn NCT03332030 - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Recruiting NCT05388370 - PASS of Paediatric Patients Initiating Selumetinib
Recruiting NCT02777775 - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. N/A
Completed NCT02944032 - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 N/A
Completed NCT01851135 - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 N/A
Completed NCT01410006 - Neurofibromatosis Type 1 Patient Registry N/A
Active, not recruiting NCT00326872 - AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Phase 2